Semaglutide
Aeterna does not sell peptides. External link, vendor independently verified.
Mechanism
Semaglutide is a glucagon-like peptide-1 receptor agonist engineered for weekly – and, in its oral form, daily – dosing. Its pharmacological reach extends well beyond the pancreatic islet, engaging circuits in the brainstem, hypothalamus, liver, and vasculature. Understanding its mechanism is understanding how a single receptor class can coordinate appetite, glucose disposal, and cardiovascular risk simultaneously.
GLP-1 receptor activation at the pancreatic islet potentiates glucose-dependent insulin secretion, increasing insulin release when glucose is elevated. This glucose dependence is one reason semaglutide differs mechanistically from older insulin secretagogues.
Central GLP-1 receptor signaling in the hypothalamus and brainstem contributes to reduced appetite and slower gastric emptying. Semaglutide’s acylated structure extends half-life through albumin binding, enabling sustained receptor engagement with once-weekly dosing.
Downstream metabolic effects include reduced energy intake and meaningful shifts in adiposity over time. Clinical imaging from the STEP programme suggests that visceral fat declines substantially alongside total weight loss.
Cardiometabolic benefit extends beyond glycemic control and weight reduction alone. Outcome trials, including SELECT, support a broader effect on cardiovascular risk in appropriately studied populations.
What we observe
Weight and sugar results people measured
The following patterns emerge consistently across the SUSTAIN, PIONEER, STEP, SELECT, and FLOW trial programmes. They represent what the published literature reports, not guarantees of individual response. Magnitude varies with baseline metabolic status, dose, duration, and adherence.
01
Glycaemic Control
02
Body Weight Reduction
03
Cardiovascular Event Reduction
04
Renal Protection
05
Hepatic Steatosis
06
Systolic Blood Pressure
Evidence
What trials showed
The evidence base for semaglutide is among the most extensive assembled for any peptide therapeutic. The trials below represent inflection points where data compelled a revision of clinical thinking. Entries reflect literature available through early 2025.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
A randomised, double-blind, placebo-controlled trial enrolling 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) and no diabetes. Participants received semaglutide 2.4 mg or placebo weekly alongside lifestyle intervention for 68 weeks. The semaglutide group achieved a mean weight reduction of 14.9% versus 2.4% for placebo. The trial established 2.4 mg as the dose that would anchor the Wegovy approval and the subsequent STEP programme.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
A landmark cardiovascular outcomes trial enrolling 17,604 adults aged ≥45 with BMI ≥27 and established cardiovascular disease but without diabetes. Participants were randomised to semaglutide 2.4 mg or placebo weekly for a median of 39.8 months. The primary endpoint – a composite of cardiovascular death, non-fatal MI, and non-fatal stroke – was reduced by 20% in the semaglutide group. The trial was the first to demonstrate cardiovascular benefit of a GLP-1 agonist in a population defined by obesity rather than diabetes, fundamentally broadening the therapeutic rationale.
Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes (FLOW)
A randomised, double-blind trial enrolling 3,533 adults with type 2 diabetes and chronic kidney disease (eGFR 24–75 mL/min/1.73 m²). Participants received semaglutide 1 mg or placebo weekly. The trial was stopped early at a pre-specified interim analysis after the data monitoring committee confirmed overwhelming efficacy. Semaglutide reduced the primary composite renal endpoint by 24% and all-cause mortality by 20%, establishing renal protection as a class effect with organ-specific trial evidence.
From lyophilized powder to a usable solution.
Peptide
5 mg lyophilized powder
Diluent
2.0 mL bacteriostatic water
Final concentration
2.5 mg/mL
01
Prepare the vial
02
Draw the diluent
03
Add slowly
04
Prepare the vial
Note
Dosing rythm
A patient titration
Dosing mirrors the FDA-approved Wegovy (semaglutide) label for chronic weight management. Administer subcutaneously once weekly. Escalate per label schedule:
• 0.25 mg once weekly x 4 weeks (initiation)
• 0.5 mg once weekly x 4 weeks
• 1.0 mg once weekly x 4 weeks
• 1.7 mg once weekly x 4 weeks
• 2.4 mg once weekly (maintenance)
Inject in abdomen, thigh, or upper arm. Administer same day each week, with or without meals. If a dose is missed and the next dose is 5+ days away, take it; otherwise skip and resume regular schedule. Source: Wegovy Prescribing Information (FDA), DailyMed.
Storage, caution, contradiction
Storage
Cold, dark, undisturbed
- Lyophilized: freeze at −20 °C (−4 °F).
- After reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and use within 28 days.
- Protect from direct light at all stages; amber vials or opaque storage recommended.
- Do not use if solution appears cloudy, discoloured, or contains visible particulate matter.
- Allow refrigerated vial to reach room temperature for 15–30 minutes before injection to reduce injection-site discomfort.
Side effects
What members describe
- Nausea - most commonly reported adverse effect; typically dose-dependent and transient, resolving within 4–8 weeks of stable dosing.
- Vomiting and diarrhoea - reported in 10–30% of participants across STEP trials; managed by slower escalation or temporary dose reduction.
- Constipation - paradoxically common alongside diarrhoea; attributed to reduced gastric motility and altered gut transit time.
- Injection-site reactions - erythema, pruritus, or mild induration; rotate injection sites systematically to minimise recurrence.
- Increased heart rate - mean increase of 2–4 bpm observed across trials; clinical significance in individuals with pre-existing tachyarrhythmia warrants evaluation.
Contradictions
Reasons to abstain
- Personal or family history of medullary thyroid carcinoma - GLP-1R agonists carry a class warning based on rodent carcinogenicity data; human risk not established but caution is standard.
- Multiple endocrine neoplasia syndrome type 2 (MEN2) - contraindicated per prescribing information across all approved semaglutide formulations.
- History of pancreatitis - causality between GLP-1 agonists and pancreatitis remains debated in the literature; clinical caution is nonetheless standard practice.
- Severe gastroparesis or gastric motility disorders - semaglutide's gastric emptying delay may exacerbate pre-existing motility dysfunction.
- Pregnancy and lactation - no adequate human safety data; animal studies show fetal harm at supratherapeutic doses; use is not supported in reproductive contexts.
Synergies
What works well with semaglutide
Semaglutide has been studied alongside several agents in both clinical and preclinical contexts. The combinations below reflect published or ongoing research pairings – not clinical recommendations. Aeterna does not prescribe, dispense, or advise on combination protocols for individuals.
FAQ
Your questions, patiently answered
The primary structural distinction is the C18 fatty diacid chain attached via a linker to lysine at position 26. This modification confers tight, reversible albumin binding, extending the half-life from liraglutide’s 13 hours to approximately 168 hours – enabling once-weekly dosing. The longer receptor occupancy also appears to produce greater central GLP-1R engagement, which may partly explain the superior weight outcomes observed in head-to-head comparisons.
The active molecule is identical, but bioavailability differs substantially. Oral semaglutide relies on co-formulation with the absorption enhancer sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SNAC), which transiently raises local gastric pH and facilitates transcellular absorption. Oral bioavailability is approximately 1%, requiring doses of 7–14 mg to achieve plasma exposures comparable to 0.5–1 mg subcutaneous. The clinical implications – particularly for weight outcomes – are still being characterised in comparative trials.
The SELECT finding challenged the assumption that GLP-1 agonist cardiovascular benefit was mediated primarily through glycaemic improvement. In a non-diabetic population, the 20% MACE reduction implicates direct vascular mechanisms – reduced endothelial inflammation, improved nitric oxide bioavailability, and attenuation of oxidative stress – as well as indirect effects through weight loss, blood pressure reduction, and lipid modulation. The relative contributions of each pathway remain an active area of mechanistic inquiry.
This is among the more consequential questions raised by the STEP programme data. Analyses of body composition in STEP 1 and STEP 5 indicate that approximately one-third of total weight lost was lean mass – a proportion broadly consistent with other caloric-deficit interventions but concerning given the absolute magnitude of weight loss at 2.4 mg. The literature does not yet establish whether resistance training, protein intake optimisation, or adjunct growth hormone secretagogue use meaningfully attenuates this loss in semaglutide-treated individuals.
The STEP 4 extension trial provides the clearest answer: participants who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of their lost weight within 48 weeks, with cardiometabolic markers returning toward baseline. This pattern is consistent with the understanding that semaglutide addresses a physiological signal – appetite and energy homeostasis – rather than the underlying adiposity set-point. The literature frames this as a chronic disease model requiring sustained treatment, not a finite course.
Yes. The GLP-1R’s broad CNS expression has prompted investigation in neurodegeneration – the EVOKE and EVOKE+ trials are examining oral semaglutide in early Alzheimer’s disease, with results anticipated in 2025. Preclinical data also suggest GLP-1R agonism may attenuate neuroinflammation and amyloid accumulation, though the translation to human outcomes remains unestablished. Addiction medicine represents another frontier, with early-phase trials examining semaglutide’s effect on alcohol use disorder – a signal first observed as an incidental finding in the STEP programme.
In the same family
Further reading in the curriculum on incretin and metabolic peptides.
Sourcing · Independently verified
When you're ready, source thoughtfully.